Shares of TRex Bio, Inc. (NASDAQ:TRXB – Get Free Report) have been given an average rating of “Buy” by the six ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $29.67.
A number of analysts recently issued reports on TRXB shares. Cantor Fitzgerald started coverage on TRex Bio in a report on Tuesday. They set an “overweight” rating on the stock. JPMorgan Chase & Co. assumed coverage on shares of TRex Bio in a research report on Tuesday. They set an “overweight” rating and a $20.00 price target on the stock. Evercore started coverage on shares of TRex Bio in a report on Tuesday. They issued a “strong-buy” rating on the stock. Wedbush assumed coverage on shares of TRex Bio in a research note on Monday. They set an “outperform” rating and a $30.00 target price on the stock. Finally, Stifel Nicolaus initiated coverage on shares of TRex Bio in a report on Tuesday. They issued a “buy” rating and a $39.00 target price for the company.
View Our Latest Report on TRex Bio
Insider Transactions at TRex Bio
In related news, major shareholder Alexandria Venture Investments bought 178,571 shares of the firm’s stock in a transaction that occurred on Tuesday, October 13th. The shares were bought at an average cost of $14.00 per share, with a total value of $2,499,994.00. Following the acquisition, the insider owned 1,346,501 shares in the company, valued at $18,851,014. This trade represents a 15.29% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
TRex Bio Trading Down 1.3%
TRXB stock opened at $13.55 on Thursday. TRex Bio has a 1-year low of $12.50 and a 1-year high of $16.56.
About TRex Bio
We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.
Featured Articles
- Five stocks we like better than TRex Bio
- 3 AI Infrastructure Plays Beyond Chipmakers
- Keurig Dr Pepper’s Beverage Growth Raises a Tough Question About Its Coffee Split
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
Receive News & Ratings for TRex Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRex Bio and related companies with MarketBeat.com's FREE daily email newsletter.
